Jessica Seeliger, Ph.D.

State University of New York, Stony Brook

Targeting Latent and Multi-Drug Resistant TB

Mycobacterium tuberculosis (Mtb), infects one-third of the world's population. Most infected individuals have latent TB infections and have no symptoms. However, decreased immune responses can trigger latent TB to reactivate and cause infectious disease. Some TB disease can become resistant to first line medications and therefore, new therapies are needed to treat multi- and extremely drug-resistant TB strains. Dr. Seeliger and team will use a novel chemical method to evaluate a family of Mtb enzymes with diverse functions essential for bacterial survival as potential drug targets. These enzymes may be promising for developing next-generation therapies against latent infections and multi-drug resistant TB

Freedom From Smoking Clinic
, | May 02, 2022
Freedom From Smoking Clinic
Virginia Beach, VA | May 10, 2022